针对炎症性肠道疾病的分子向疗法的研究进展
Nan Liu1,2, Chengye Pan3, Lishuai Qu4
1Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, 19 Qixiu Road, Nantong, Jiangsu, China.
分子向疗法为炎症性肠病 (IBD) 管理提供了更好的疗效和安全性,特别是在中国. 研究重点是优化治疗序列和整合生物标志物,以实现性结肠炎和克罗恩病的个性化护理.
科学领域:
- 胃肠病学和免疫学,专注于炎症性肠病 (IBD) 病原和治疗干预.
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),在中国的患病率呈上升趋势,这是城市化和生活方式转变所推动的.
- 传统的IBD治疗对中度至重度病例的疗效和安全性有局限性,需要基于先进的精确疗法.
- 病变发生涉及不调节的炎症通路,如NF-κB,IL-23/Th17和TGF-β,这些通路是新型分子疗法所准的.
研究的目的:
- 审查IBD分子向治疗的最新进展,澄清机制并评估新兴药物的疗效和安全性.
- 为临床决策提供信息,并指导IBD治疗的未来研究方向.
主要方法:
- 在PubMed,Embase和Cochrane图书馆进行全面的文献搜索 (2014-2025年).
- 关键词包括"炎症性肠病"",分子向治疗"",TNF抑制剂"",JAK抑制剂"和"生物标志物".
- 分析了500多项临床试验,元分析和机制研究.
主要成果:
- 分子向疗法,包括TNF-α抑制剂,整合素抗剂和JAK抑制剂,显示IBD缓解率显著改善.
- 个性化治疗选择得到了像miR-21和转录组签名这样的生物标志物的支持.
- 治疗策略正在从单个点转向多途径调制,增强临床管理.
结论:
- 分子向疗法代表了IBD管理的变革性方法,提供比传统治疗更精确和更有效的选择.
- 仍然存在挑战,包括初级不响应,二次响应丧失和安全问题 (例如感染,心血管事件).
- 进一步的研究对于完善治疗序列,整合生物标志物和优化新型IBD病原体的风险益处概况至关重要.
更多相关视频
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
